Is TB-500 Legal in Florida? Federal Law, State Rules, and How to Get It
Key numbers
- 2 mg to 15 mgVial sizes in which the research-use-only peptide powder is sold onlineSource: fda.gov, as cited Nov 7, 2026
- 3 mg/mLConcentration of the injectable powder proposed in the nomination FDA reviewedSource: fda.gov, as cited Nov 7, 2026
- 5 mg/5 mgStrength of a BPC-157 plus TB-500 injection product linked to a reported adverse reactionSource: fda.gov, as cited Nov 7, 2026
See the public record for TB-500
At a glance
- FDA approval / None; no FDA-approved drug contains TB-500 [1]
- FDA compounding lists / Not in any category on the pharmacy list or the outsourcing facility list [2][5][3]
- Advisory committee / Voted on 23 July 2026 to recommend adding it; advice only, not binding [6][4]
- HHS policy / Draft enforcement-discretion notice filed 28 October 2026; not an approval and not a listing [4]
- State-licensed pharmacies / The federal documents apply to state-licensed pharmacies in general, which includes Florida's [4][10]
- Human safety data / FDA found no human exposure data and no toxicity studies [1]
- Sport / Prohibited at all times under WADA S2.3 [7][8]
What TB-500 actually is
TB-500 is a synthetic, N-acetylated 7-amino-acid fragment of the 43-amino-acid protein thymosin beta-4 — residues 17 to 23, with a molecular weight of about 889 g/mol [1]. It is not full-length thymosin beta-4, and it is not thymosin alpha-1. 'TB-500' is a common name rather than an official drug name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].
It appears to have been first synthesized in 2003 from thymosin beta-4, and a veterinary preparation marketed to boost performance in horses and greyhounds appeared in 2011. It is sold online as a research-use-only injectable powder in vials of 2 mg to 15 mg, alone or blended with BPC-157 [1]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
Is TB-500 FDA-approved?
No. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].
Where TB-500 sits in the federal compounding rules
A state-licensed pharmacy may compound with a bulk substance only if it complies with a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on FDA's bulks list [3]. TB-500 meets none of those conditions. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) or on the list for outsourcing facilities (updated 21 March 2025), and FDA's policy of generally not acting against compounders that meet the category 1 conditions does not cover it [2][5][3].
TB-500 does appear on FDA's page about bulk substances that may present significant safety risks (content dated 22 April 2026), in the 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them [9]. Removal from category 2 was not a finding that it is safe. FDA's stated concerns are that it has not identified any human exposure data on drug products containing the fragment, that it lacks important safety information, and that injectable peptides may pose an immunogenicity risk from aggregation and peptide-related impurities [9].
The July 2026 advisory committee vote
FDA staff proposed in a July 2026 briefing document that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list. Their reasons: the substance is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data); historical use is unclear; there is no evidence of effectiveness for wound healing, the use FDA evaluated; there are no human data of any kind; injection carries immunogenicity risk; and FDA-approved wound treatments already exist [1].
FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 and voted in favor of adding it to the bulks list, against the staff recommendation [6][4]. That vote is advice only and is not binding. TB-500 is not on the list, and adding it requires formal rulemaking [4].
The October 2026 HHS draft policy
HHS filed a draft enforcement-discretion policy for compounding with certain peptides on 28 October 2026 (Federal Register document 2026-22192, publication scheduled for 30 October 2026, comments due two weeks after publication) [4]. It names TB-500 among six peptides, alongside BPC-157, epitalon, KPV, MOTS-c and Semax, and covers TB-500 acetate given by subcutaneous or intramuscular injection [10]. Under the draft, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with it if the policy's conditions are met — for example a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' [10].
The draft is not an approval and does not put TB-500 on any list. The notice states that it does not establish any rights for any person and is not binding on HHS or the public, and that HHS may revisit it if a safety signal or product quality issue arises [4]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [4].
What this means in Florida
The FDA and HHS documents refer to state-licensed pharmacies and licensed physicians in general, which includes those licensed in Florida [3][4][10]. This page does not cover Florida statutes or Florida Board of Pharmacy rules.
What people on Reddit report
Commenters on the July FDA committee vote disagree about whether pharmacies can lawfully compound these peptides now. Some are pharmacy owners or pharmacy patients.
The majority, such as all the ones being reviewed by the committee are currently on the do not compound list. So any pharmacy that would be compounding them right now would be doing so at a huge risk to lose their license or may not actually be legit pharmacies.Read the source discussion
I thought that as of right now, there was kind of a grey area in the system that allows for pharmacies and doctors to do that and it's not actually illegal.Read the source discussion
Questions worth asking
What is known about safety in humans
FDA searched PubMed, Embase, ClinicalTrials.gov and other sources and found no article in which TB-500 was given to a human, and none of the three papers the nominator cited involved TB-500 in humans [1]. There is no approved dose and no human dosing study; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for subcutaneous or intramuscular injection [1]. In an in-vitro scratch-wound test, TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures, while a shorter metabolite (N-acetylated LKKTE) did show activity [1].
FDA's adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and its food and supplement complaint system (1 January 2004 to 10 March 2025) retrieved two cases about 'blended TB-500 and BPC-157' with no safety assessment. FDA found no published case reports, no nonclinical toxicity studies of TB-500, and no study of its immunogenicity or aggregation [1].
FDA's BPC-157 review describes a 40-year-old woman who used a research-purposes-only BPC-157 plus TB-500 (5 mg/5 mg) injection product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, which recurred when she re-tried the product two weeks later; because the product held two peptides, FDA said it cannot tell whether either one caused it [11].
Full-length thymosin beta-4 trials are a different product
A phase 1 study gave recombinant human thymosin beta-4 intravenously to 54 healthy volunteers in single doses of 0.05 to 25 microgram/kg, and to 30 volunteers at 0.5, 2 or 5 microgram/kg daily for 10 days; adverse events were mild to moderate, with no dose-limiting toxicity or serious adverse events [12]. A phase 2 dry-eye trial of 0.1% thymosin beta-4 drops in 72 adults over 28 days found no significant difference from placebo on either primary endpoint, ocular discomfort or inferior corneal staining [13]. Neither study tested TB-500, and neither shows that TB-500 works or is safe [1].
Sport
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, growth factors and growth factor modulators [7]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances. It is on the 2026 List, in force since 1 January 2026, and stays on the 2027 List [7][8].
Frequently asked questions
Is TB-500 legal in Florida?
Can a Florida pharmacy compound TB-500?
Is TB-500 the same as thymosin beta-4?
Has TB-500 been studied in humans?
Is TB-500 banned in sport?
References
Show all 14 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- U.S. Food and Drug Administration.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- Reddit participants. The FDA committee just voted yes on BPC, TB-500, and 4 others. (r/NTNPerformance). Accessed 2026-11-11.